Newamsterdam Pharma(NAMS.US)

Event Tracking

Nov11

TD Cowen Maintains Buy Rating on NewAmsterdam Pharma

08:17

Nov10

RBC Capital Analyst Maintains Buy Rating on NewAmsterdam Pharma

12:23

William Blair cuts NewAmsterdam Pharma's 2025 EPS forecast

06:53

Nov7

NewAmsterdam Pharma Reports Q3 2025 Loss of $72 Million

06:57

Nov6

Newamsterdam Pharma released FY2025 9 Months earnings on November 5, 2025 (EST), actual revenue USD 22.47 M, actual EPS USD -1.0968

04:00

Newamsterdam Pharma released FY2025 Q3 earnings on November 5, 2025 (EST), actual revenue USD 348 K (forecast USD 5.342 M), actual EPS USD -0.605 (forecast USD -0.4043)

04:00

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 348 K, Net Income -72.01 M, EPS -0.605

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 19.15 M, Net Income -17.36 M, EPS -0.1464

May8

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 2.978 M, Net Income -39.53 M, EPS -0.3403

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change